Your browser doesn't support javascript.
loading
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.
Kumar, Sushil; Zeng, Zexian; Bagati, Archis; Tay, Rong En; Sanz, Lionel A; Hartono, Stella R; Ito, Yoshinaga; Abderazzaq, Fieda; Hatchi, Elodie; Jiang, Peng; Cartwright, Adam N R; Olawoyin, Olamide; Mathewson, Nathan D; Pyrdol, Jason W; Li, Mamie Z; Doench, John G; Booker, Matthew A; Tolstorukov, Michael Y; Elledge, Stephen J; Chédin, Frédéric; Liu, X Shirley; Wucherpfennig, Kai W.
Afiliação
  • Kumar S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zeng Z; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Bagati A; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Tay RE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sanz LA; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Hartono SR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ito Y; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Abderazzaq F; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, California.
  • Hatchi E; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, California.
  • Jiang P; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cartwright ANR; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Olawoyin O; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mathewson ND; Harvard Medical School, Boston, Massachusetts.
  • Pyrdol JW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li MZ; Harvard Medical School, Boston, Massachusetts.
  • Doench JG; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Booker MA; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Tolstorukov MY; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Elledge SJ; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Chédin F; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Liu XS; Yale School of Medicine, New Haven, Connecticut.
  • Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Discov ; 11(8): 2050-2071, 2021 08.
Article em En | MEDLINE | ID: mdl-33707234
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína-Arginina N-Metiltransferases / Inibidores de Checkpoint Imunológico / Neoplasias Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína-Arginina N-Metiltransferases / Inibidores de Checkpoint Imunológico / Neoplasias Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos